Clinical trials: Cardiotoxicity
Breast Cancer
Acute Exercise Cardioprotection From Doxorubicin
In rodents, a single bout of exercise prior to injection of a chemotherapy agent used to treat breast cancer prevents or attenuates a number of markers of cardiac injury.
- Trial name
- NCT02006979
- Testing
- exercise
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- University of British Columbia
Breast Neoplasms
Attenuating Cancer Treatment-related Toxicity in Oncology Patients With a Tailored Physical Exercise Program
The aim of this study is to determine if therapeutic exercise before anticancer treatment will mitigate the onset or extent of cardiotoxicity comparing to therapeutic exercise performed during anticancer treatment.
- Trial name
- ATOPE (NCT03787966)
- Testing
- ATOPE-B, ATOPE-I
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Universidad de Granada
Breast Cancer, Cardiac Toxicity
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00436566
- Testing
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Mayo Clinic
Cancer, Heart Failure
A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients
Purpose：1. Preliminary evaluation of the preventive effect of DH001 on doxorubicin-induced cardiotoxicity in cancer patients 2.To explore appropriate dosages to provide basis for dosages in subsequent confirmatory studies 3.To…
- Conditions
- Cancer, Heart Failure, Arrhythmia, Doxorubicin Induced Cardiomyopathy
- Trial name
- NCT06092606
- Testing
- Trial group: DH001 low-dose group, Trial group: DH001 high-dose group
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Monyan Pharmaceutical (Shanghai) Co., Ltd.
Cardiotoxicity
Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients
To assess the role of myocardial oedema on CMR (T2 mapping) after radiation therapy and cardiotoxic systemic therapy in predicting the incidence of cardiotoxicity, defined as by consensus guidelines* (decline of LVEF ≥10% points…
- Trial name
- CARDIOTOX (NCT04790266)
- Testing
- Cardiac MRI
- Where
- Switzerland
- Volunteers
- 150 people
- Sponsor
- Oncology Institute of Southern Switzerland
Breast Cancer
Cardiotoxicity in Breast Cancer Patients
The goal of this clinical trial is to learn if dapagliflozin drug has a cardioprotective effect against anthracyclines-induced cardiotoxicity. It will also learn about the safety of dapagliflozin drug.
- Trial name
- NCT06491680
- Testing
- Dapagliflozin 10mg Tab
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Helwan University
Non Hodgkin Lymphoma, DLBCL
Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma
Survivors of non-Hodgkin lymphoma and a control group will be screened for (sub)clinical cardiovascular disease, to assess the influence of contemporary treatments on risk and burden of (sub)clinical cardiovascular disease and…
- Conditions
- Non Hodgkin Lymphoma, DLBCL, Cardiovascular Diseases, Cardiomyopathies
- Trial name
- CLARITY (NCT07041827)
- Testing
- Cardiovascular assessment
- Where
- Netherlands
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- The Netherlands Cancer Institute
HIV Infections
Long-term Effects of Highly Active Anti-Retroviral Therapy on HIV-Infected Children
This study will use the NIH-sponsored Women and Infants Transmission Study (WITS) and the Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2) HIV-infected pediatric cohorts to…
- Trial name
- NCT00260806
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 71 people
- Sponsor
- University of Miami
Doxorubicin Induced Cardiotoxicity, Doxorubicin Induced Cardiomyopathy
The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity
Breast cancer is one of the world's most common cancers in females. Most of the chemotherapy protocols used to treat breast cancer involve doxorubicin. Doxorubicin has a very significant antitumor effect on breast tumors.
- Conditions
- Doxorubicin Induced Cardiotoxicity, Doxorubicin Induced Cardiomyopathy, Doxorubicin, Doxorubicin Adverse Reaction
- Trial name
- NICBREASTRCT (NCT07897409)
- Testing
- Nicorandil Oral Tablet, Adriamycin (Doxorubicin)
- Where
- Egypt
- Volunteers
- 146 people
- Sponsor
- Universiti Sains Malaysia
Non-small Cell Lung Cancer, Radiation Toxicity
Detecting Radiation-Induced Cardiac Toxicity After Non-Small Cell Lung Cancer Radiotherapy
Lung cancer is the most common cause of cancer death in Canada. For approximately 30% of patients that present with locally-advanced non-small cell lung cancer (NSCLC), the standard treatment is curative-intent concurrent…
- Trial name
- RICT-LUNG (NCT03416972)
- Testing
- Standard platinum-based chemoradiotherapy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Non Small Cell Lung Cancer, Nephropathy
Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Cisplatin Among Egyptian Non-small Cell Lung Cancer Patients
Lung cancer is the leading cause of death worldwide, with non-small-cell lung cancer (NSCLC) being the most common histotype according to the global cancer observatory 2022.
- Conditions
- Non Small Cell Lung Cancer, Nephropathy, Cardiotoxicity
- Trial name
- NCT05746598
- Testing
- Cisplatin injection
- Where
- Egypt
- Volunteers
- 178 people
- Sponsor
- Ain Shams University
Anthracycline-induced Cardiotoxicity
Preventing Cardiac Sequelae in Pediatric Cancer Survivors
Cancer therapy can place childhood cancer survivors at increased risk for heart disease which can lead to significant illness or early death.
- Trial name
- PCS2 (NCT01805778)
- Where
- 6 sites in United States, Canada
- Volunteers
- 1,128 people
- Sponsor
- The Hospital for Sick Children
Non-small Cell Lung Cancer, Esophageal Cancer
Radiation-induced Toxicity of the Heart
Late side effects in radio(chemo)therapy [R(CH)T] pose a critical limitation to patients' overall survival and quality of life. Even though toxicities of the heart are highly relevant for patients with cancer in the thoracic…
- Conditions
- Non-small Cell Lung Cancer, Esophageal Cancer, Breast Cancer Female
- Trial name
- CorTox (NCT06986291)
- Testing
- Imaging and biomarkers
- Where
- Germany
- Volunteers
- 325 people
- Sponsor
- Technische Universität Dresden
Cardiotoxicity, Cardiovascular Disease
Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses
The present study aims to investigate the chronic effect of treatment with doxorubicin and cyclophosphamide on neurovascular control and blood pressure in women undergoing adjuvant treatment for breast cancer.
- Conditions
- Cardiotoxicity, Cardiovascular Disease, Neurovascular Disorder, Endothelial Disfunction
- Trial name
- NCT04568161
- Testing
- Physical Characteristics, Muscular Sympathetic Nervous Activity, Cardiac Function
- Where
- Brazil
- Volunteers
- 15 people
- Sponsor
- University of Sao Paulo General Hospital
Cardiac Toxicity, Antitumor Drugs
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
According to the existing clinical data in our hospital, retrospective study was conducted to screen the risk factors with predictive value for TRC(trastuzumab-related cardiotoxicity) risk, and to construct the risk prediction…
- Conditions
- Cardiac Toxicity, Antitumor Drugs, Breast Cancer
- Trial name
- NCT04962425
- Testing
- Trastuzumab
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Peking University Third Hospital
Breast Cancer
Circulating MicroRNA as Biomarker of Cardiotoxicity in Breast Cancer
In the proposed project the investigators will asses whether changes in expression of selected circulating microRNAs in serum could comprise a sensitive and specific biomarker of cardiotoxicity in cancer patients treated with…
- Trial name
- NCT02065908
- Where
- 3 sites in Poland
- Volunteers
- 128 people
- Sponsor
- West Pomeranian Cancer Center
Cardiotoxicity, Acute Myeloid Leukemia in Children
Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia
Prevention and early detection of chemotherapy-induced cardiotoxicity in children with bone tumors and Acute Myeloid Leukemia by giving capoten
- Conditions
- Cardiotoxicity, Acute Myeloid Leukemia in Children, Bone Tumor
- Trial name
- NCT03389724
- Testing
- Capoten®
- Where
- Egypt
- Volunteers
- 245 people
- Sponsor
- Children's Cancer Hospital Egypt 57357
Heart Failure, Cardiotoxicity
The Harmonized Interventions to Maintain Health Via Appropriate Risk Factor Modification and Lifestyle Changes in Pediatric, Adolescent and Young Adult Cancer Survivors Pilot Study
Cardiovascular disease (CVD) is a major contributor to morbidity and mortality in pediatric, adolescent and young adult (AYA) cancer survivors (hereafter referred to as PAYA-CS).
- Conditions
- Heart Failure, Cardiotoxicity, Cancer
- Trial name
- HIMALAYAS-P (NCT04598646)
- Testing
- Cardio-oncology Rehabilitation (CORE), Support
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Breast Cancer
Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
This multicenter clinical study aims to build an intelligent and accurate diagnosis and dynamic prediction and early warning model of cardiotoxicity due to anthracycline-based breast cancer chemotherapy, clarify the value of the…
- Trial name
- NCT06282796
- Testing
- Echocardiography
- Where
- 5 sites in China
- Volunteers
- 600 people
- Sponsor
- First Hospital of China Medical University
Atrial Fibrillation
Subcutaneous Cardiac Monitoring of Patients With BTK Inhibitors
The goal of this clinical trial is to screen all types of electrocardiographic changes and rhythm disorders in adult patients with a hematologic malignancy requiring a treatment by Bruton's tyrosine kinase (BTK) inhibitor…
- Trial name
- IRAF-ISCM (NCT06029166)
- Testing
- Insertable subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Caen